ACADIA Pharmaceuticals, Inc. (ACAD)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals, Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD). Investors who purchased ACADIA securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether ACADIA and certain of its officers and/or directors have violated federal securities laws.
On June 17, 2022, Acadia issued a press release “announc[ing] the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).” Acadia reported that “[t]he PDAC voted 9 to 3 that the evidence presented does not support a conclusion that pimavanserin is effective for the treatment of hallucinations and delusions in the ADP population.” Following this announcement, trading in Acadia shares was temporarily halted. When trading resumed on June 21, 2022, Acadia’s stock price fell $6.50 per share, or 33.32%, to close at $13.01 per share on June 21, 2022.
If you are aware of any facts relating to this investigation or purchased ACADIA shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.